News & Updates

Pain and quality of life (QoL) outcomes from the phase III PANOVA-3 trial reinforce the role of tumour treating fields (TTFields) therapy when added to a chemotherapeutic regimen consisting of gemcitabine/nab-paclitaxel (GnP) for the treatment of individuals with locally advanced pancreatic adenocarcinoma.

The phase IIIb SIERRA study has shown an acceptable safety profile for the single tremelimumab regular interval durvalumab (STRIDE) regimen as first-line treatment for patients with hepatocellular carcinoma (HCC) who have a poor prognosis.

Patients with resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma demonstrate significant improvements in event-free survival (EFS) following treatment with durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy compared with placebo plus FLOT, as shown by the results of the phase III MATTERHORN study.

In a systematic review and meta-analysis evaluating surgical outcomes in low rectal cancer patients who underwent early vs late ileostomy reversal, the former appears to be less beneficial than the latter in terms of surgical complications.

For patients who have undergone curative resection for nonmetastatic colorectal cancer (CRC), performing circulating tumour DNA (ctDNA) methylation analysis during surveillance facilitates earlier detection of recurrences suitable for curative therapy, according to interim data from the phase III FIND trial.